The global sales of pharma-grade plastic packaging are estimated to be worth USD 56.6 billion in 2024 and are anticipated to reach a value of USD 74.2 billion by 2034. Sales are projected to rise at a CAGR of 3.0% over the forecast period between 2024 and 2034. The revenue generated by pharma-grade plastic packaging in 2023 was USD 54 billion. The industry is anticipated to exhibit a Y-o-Y growth of 2.5% in 2024.
Pharma-grade plastic bottles are mostly sold in the global market driven by their versatility and diverse applications among the different pharmaceutical products. Plastic bottles can be used for sold medicines, liquid syrups, and topical medication.
Plastic bottles are light in weight, durable and inexpensive which makes them a preferred option for pharmaceutical companies when compared to other materials. Plastic bottles also provide an excellent barrier to the medications and protect them from external factors preventing contamination. The rising focus on sustainability has pushed the use of recycled plastic bottles driven by advanced manufacturing and recycling technologies.
Global Pharma Grade Plastic Packaging Industry Assessment
Attributes | Key Insights |
---|---|
Historical Size, 2023 | USD 54 billion |
Estimated Size, 2024 | USD 56.6 billion |
Projected Size, 2034 | USD 74.2 billion |
Value-based CAGR (2024 to 2034) | 3.0% |
In pharma grade plastic packaging, polyethylene is mostly used in manufacturing pharmaceutical packaging. The material is more favoured by the companies because of its chemical resistance, durability, and moisture barrier properties.
This material is highly recyclable and fulfill all the standard regulatory requirements for pharmaceutical industry. The easy molding ability and advanced technology in manufacturing has increased the use of polyethylene especially high-density polyethylene (HDPE) in pharmaceutical packaging.
The pharma grade plastic packaging industry is set to experience moderate growth during the forecast period. It is projected to create an incremental opportunity of USD 19.2 billion and is predicted to rise 1.3 times the current market value through 2034.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The above table presents the expected CAGR for the global pharma grade plastic packaging market over several semi-annual periods spanning from 2024 to 2034. In the first half (H1) of the decade from 2023 to 2033, the business is predicted to surge at a CAGR of 3.2%, followed by a slightly lower growth rate of 2.9% in the second half (H2) of the same decade.
Particular | Value CAGR |
---|---|
H1 | 3.2% (2023 to 2033) |
H2 | 2.9% (2023 to 2033) |
H1 | 2.8% (2024 to 2034) |
H2 | 3.1% (2024 to 2034) |
Moving into the subsequent period, from H1 2024 to H2 2034, the CAGR is projected to increase slightly to 2.8% in the first half and remain relatively moderate at 3.1% in the second half. In the first half (H1) the market witnessed a decrease of 40 BPS while in the second half (H2), the market witnessed an increase of 20 BPS.
Rising Need for Personalized Packaging Due to Pharmacogenomics
The rising number of deaths due to adverse drug reactions (ADR) has been creating huge demand and increasing research for personalized medications.
The condition also known as pharmacogenomics is a new and trending healthcare service that targets tailor-made treatments and medicines specifically for individuals. These medications and dosages are genetically customized for the patients to reduce adverse drug reactions and improve the treatment efficacy.
For instance, the HIV medication is done by genetic tests for genome tracing projects before the administration. Also, Pharmacogenomics (PGx) is expanding into different applications in the healthcare sector especially in the United States including community pharmacies.
The rising trend of personalized packaging is becoming more prevalent in future and create the demand for unique packaging solutions. This also generates the demand for contract manufacturing organizations to meet the tailor-made pharmaceutical packaging demand.
Elevated Demand for Sustainable Packaging Solutions Healthcare
Pharma-grade plastic packaging is highly affected by the sustainability issues which has given a driving force to recyclable and biodegradable packaging solutions in future. The global shift to eco-conscious practices, lifestyle choices, and sustainability matrices has become critical need of the current period.
For instance, a survey revealed that more than 50% of people in America have opted for sustainable packaging in the pharmaceutical industry. The consumers are aligning with the brands who are experimenting with eco-friendly packaging solutions. Compostable, and biodegradable plastic packaging has become a different factor that will gain further traction in the upcoming period.
Recently, Bayer in association with Pulpac has announced that they are using dry molded fiber technology by joining the blister pack collective initiative which reduces the 100,000 tonnes of waste in medicine plastic packaging.
Post-consumer recycled plastic has gained significant importance in the recent period which is priming the circular economy and receding plastic waste. While there are certain challenges associated with it that need to be removed. PCR helps in sustainability by reducing plastic waste, and carbon footprints.
Pharma-grade packaging made from PCR helps maintain product integrity by reducing contamination from bacteria, and UV, and maintaining inert quantities of maledictions. Sustainability in pharma grade packaging will be a continued focus for the industry in 2024 and beyond.
The global pharma-grade plastic packaging industry recorded a CAGR of 2.1% during the historical period between 2019 and 2023. The growth of the pharma-grade plastic packaging industry was positive as it reached a value of USD 54 billion in 2023 from USD 51 billion in 2019.
Pharma-grade plastic packaging is majorly driven by the need for materials that provide safety and efficacy to drugs, medicines and other pharmaceutical products. Pharma-grade plastic packaging is important for offering tamper evidence and child resistance for preventing product counterfeiting. Also, the materials need to be of high quality meeting the stringent regulatory standards which has pushed the need for pharma grade plastic packaging.
The increasing demand for customization and designs for end-use applications to generate a positive impression and branding to please the customers. The market is driven by the need for versatile, secure, and eco-friendly packaging solutions along with protecting pharma products from contamination for consumer safety and regulatory implications.
Pharma-grade plastic packaging solutions must be well regulated with industry standards set by the government and associations including the United States Pharmacopeia (USP), the European Pharmacopoeia (Ph. Eur.), and the International Organization for Standardization (ISO).
The rising focus on safety, hygiene, and personal care puts more importance on compliance with these standards to maintain the safety, quality and performance of medications and drugs. This compliance also helps to gain consumer trust in your product which is necessary for growth.
Pharma-grade plastic packaging is also becoming smart by using advanced technology. The inclusion of smart features in pharmaceutical packaging helps in original product identification, eliminating moisture, extending shelf life, and tracking and trace of packaging. This has also included the connection of patients’ devices and offers easy patient accessibility.
Tamper-evident packaging has also become essential due to increasing tampering and counterfeiting. Biodegradable and recyclable packaging also become essential in the market to reduce waste and highlight the importance of innovative packaging solutions.
Pharma-grade packaging is becoming an innovative product launched and development. The packaging comes with seals, labels, and closures that reveal the tamper evidence. This innovative packaging is essential in the rise of pharmaceutical-grade plastic packaging for reducing tampering and counterfeiting.
Tier 1 companies in the global pharma grade plastic packaging industry include Nolato AB, Gerresheimer AG, Berry Global, Inc., Amcor plc, AptarGroup, Inc, West Pharmaceutical Services, Inc., Schott AG with market revenue above USD 2 billion.
These manufacturers are market leaders in pharma grade plastic packaging within global industry having extensive production capacity, different product offerings, and extensive manufacturing expertise. These companies are capturing around 10% to 20% of global market share in the pharma grade plastic packaging industry.
Tier 2 of the global pharma grade plastic packaging industry incorporates companies like Drug Plastics Group, Alpla Werke Alwin Lehner GmbH & Co KG, Parekhplast India Limited, Nipro Corporation, West Pharmaceutical Services, Inc., Alpha Packaging Company, Mykron Plus India Pvt. Ltd, Comar LLC , Alpack Inc with revenue of USD 1 to 2 billion.
They have limited presence, and well-maintained knowledge but may not have expertise and advanced manufacturing technology. These manufacture have mostly limited regional presence having knowledge and demand of regional market dynamics.
Tier 3 category in the global pharma grade plastic packaging market includes the small-scale players of the region with revenue below USD 1 million. These companies fulfil the local market demand and are recognized as an unorganized market. They have a country level presence, limited manufacturing facilities, and expertise in local market needs. They are well established in local market and fulfill the local market demands.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The section below covers the industry analysis of the pharma grade plastic packaging market for different countries. Market demand analysis on key countries in several regions of the globe, including North America, South Asia & Pacific, East Asia, Western Europe, Eastern Europe, and others, is provided.
North America and Europe are leading in the market with maximum market share. South Asia Pacific, East Asia, and MEA has anticipated to record high growth rate during forecast period.
Countries | Value CAGR (2024 to 2034) |
---|---|
USA | 1.8% |
Germany | 1.2% |
UK | 1.6% |
Canada | 2.6% |
India | 4.1% |
China | 3.9% |
Japan | 2.8% |
Brazil | 3.3% |
India is expected to hold almost 50% the value share of the South Asia and Pacific region by 2034. The India Brand Equity Foundation (IBEF) have recently reported that the Indian pharmaceutical industry is anticipated to register a total valuation of approximately USD 65 billion by the end of 2024 and reach around USD 130 billion by 2030 end.
Elevating demand from the pharmaceutical industry in the country for safe and secure packaging using sustainable materials is projected to increase the adoption of pharma-grade plastic packaging solutions. The rising prevalence of chronic diseases, the emergence of sudden pandemics, and high healthcare expenditures in India are also contributing to market growth.
Aged people are more prone to chronic diseases which is an effective driving factor for the vaccine packaging market. In Japan, 1 out of 10 people are above 80 years or older and the country is rated to have the world’s oldest population.
According to the World Economic Forum, almost 1/3rd of Japan's population is over 65 years which accounts for 36.23 million people contributing to the geriatric population. The rising age results in an increasing number of diseases and health issues which generate the demand for pharma grade plastic packaging in the country. Japan is anticipated to at 2.8% CAGR and capture 22% of market share in East Asia by 2034 end.
The USA leads in North America with more than 76% of the market share in 2024 and is anticipated to expand at 1.8% CAGR by the end of the assessment period. According to the Centre for Disease Control and Prevention (CDC), around 1,603,844 cancer cases were reported in the United States out of which 602,347 died due to cancer in the year 2020. 403 new cancer cases are being reported for every 100,000 people out of which 104 died because of cancer.
These deaths are because of the unavailability of treatments and medications for treating and saving patients. This is expected to create a focus on clinical trials to develop drugs for cancer treatment in the USA which significantly drive the demand for pharma grade plastic packaging including vials, syringes, etc. in the region for prevention and treatment of such diseases.
Several prominent players in the pharma grade plastic packaging market are significantly investing in innovation, research, and development to discover new applications and enhance their offerings. Manufactures prioritize safety, product quality, and customer satisfaction to expand their customer base.
Key manufacturers of pharma grade plastic packaging are focusing on developing recycled material packaging and developing packaging solutions to meet sustainability demand. They are adopting a merger & acquisition strategy to expand their resources and are developing new products to meet customer needs.
Recent Industry Developments in Pharma Grade Plastic Packaging Market
Pharma grade plastic packaging industry is divided into bottles, blisters, vials & ampoules, syringes, pouches, and other (tubes, cartridges).
Pharma grade plastic packaging industry is segregated into polyethylene (PE), polypropylene (PP), polyvinyl chloride (PVC), polyethylene terephthalate (pet), polystyrene (PS), acrylonitrile butadiene styrene (ABS), polycarbonate (PC), and other.
The industry is classified by oral drugs, injectable drugs, topical medications, inhalable medications, transdermal patches, and diagnostic devices.
The industry is classified by end use as pharmaceutical companies, biotechnology companies, contract manufacturing organizations (CMO), hospitals and clinics and research laboratories.
Key countries of North America, Latin America, Western Europe, Eastern Europe, South Asia & Pacific, East Asia, and Middle East and Africa (MEA), have been covered in the report.
The global pharma grade plastic packaging industry is projected to witness CAGR of 3.0% between 2024 and 2034.
The global pharma grade plastic packaging industry stood at USD 54 billion in 2023.
The global pharma grade plastic packaging industry is anticipated to reach USD 74.2 billion by 2034 end.
South Asia and Pacific is set to record the highest CAGR of 4.8% in the assessment period.
The key players operating in the global pharma grade plastic packaging industry include includes Nolato AB, Gerresheimer AG, Berry Global, Inc., Amcor plc, AptarGroup, Inc, West Pharmaceutical Services, Inc., Schott AG.
1. Executive Summary 2. Industry Introduction 3. Market Trends and Success Factors 4. Market Background 5. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034 6. Pricing Analysis 7. Global Market Value (USD) Analysis 2019 to 2023 and Forecast 2024 to 2034 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product 8.1. Bottles 8.2. Blisters 8.3. Vials & Ampoules 8.4. Syringes 8.5. Pouches 8.6. Other (Tubes, Cartridges) 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Material Type 9.1. Polyethylene (PE) 9.2. Polypropylene (PP) 9.3. Polyvinyl Chloride (PVC) 9.4. Polyethylene Terephthalate (PET) 9.5. Polystyrene (PS) 9.6. Acrylonitrile Butadiene Styrene (ABS) 9.7. Polycarbonate (PC) 9.8. Others 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Application 10.1. Oral Drugs 10.2. Injectable Drugs 10.3. Topical Medications 10.4. Inhalable Medications 10.5. Transdermal Patches 10.6. Diagnostic Devices 11. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End-User 11.1. Pharmaceutical Companies 11.2. Biotechnology Companies 11.3. Contract Manufacturing Organizations (CMOs) 11.4. Hospitals and Clinics 11.5. Research Laboratories 12. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region 12.1. North America 12.2. Latin America 12.3. East Asia 12.4. South Asia & Pacific 12.5. Western Europe 12.6. Eastern Europe 12.7. Middle East & Africa 13. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Market Segments and Country 14. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Market Segments and Country 15. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Market Segments and Country 16. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Market Segments and Country 17. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Market Segments and Country 18. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Market Segments and Country 19. Middle East and Africa (MEA) Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Market Segments and Country 20. Sales Analysis 2024 & 2034 by Key Market Segments for 30 Countries 21. Competition Outlook including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 22. Company Profile 22.1. Nolato AB 22.2. Gerresheimer AG 22.3. Berry Global, Inc. 22.4. Amcor plc 22.5. AptarGroup, Inc 22.6. West Pharmaceutical Services, Inc. 22.7. Schott AG 22.8. Drug Plastics Group 22.9. Alpla Werke Alwin Lehner GmbH & Co KG 22.10. Parekhplast India Limited 22.11. Nipro Corporation 22.12. West Pharmaceutical Services, Inc. 22.13. Alpha Packaging Company 22.14. Mykron Plus India Pvt. Ltd 22.15. Comar LLC 22.16. Alpack Inc. 22.17. Bormioli Pharma S.p.a. 22.18. United States Plastic Corporation 22.19. Origin Pharma Packaging 22.20. Pretium Packaging 22.21. Weener Plastics Group BV 22.22. Pro-Pac Packaging Group 22.23. Silgan Holdings Inc 22.24. Frapak Packaging b.v. 22.25. Altium Packaging 22.26. Klöckner Pentaplast Group 22.27. Becton, Dickinson and Company 22.28. Mondi Plc 22.29. Sealed Air Corporation 22.30. Constantia Flexibles Group GmbH 22.31. Wipak Group
Explore Packaging Insights
View Reports